Evidence map›Paper›PMID 27582674›Full record

ArticleDigital journal of ophthalmology : DJO2016

A cluster of presumed, noninfectious endophthalmitis after intravitreal injection of bevacizumab: long-term follow-up.

Federico Ricci, Antonio Calabrese, Cecilia De Felici, Filippo Missiroli, Marco Pileri, Federico Regine

Open access · diamondAbstract read
In one paragraph

Article in Digital journal of ophthalmology : DJO, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Federico RicciUOSD Patologie Retiniche, Fondazione Policlinico di Tor Vergata Roma, Italy;
Antonio CalabreseUOSD Patologie Retiniche, Fondazione Policlinico di Tor Vergata Roma, Italy;
Cecilia De FeliciUOSD Patologie Retiniche, Fondazione Policlinico di Tor Vergata Roma, Italy;
Filippo MissiroliUOSD Patologie Retiniche, Fondazione Policlinico di Tor Vergata Roma, Italy;
Marco PileriUOC Oftalmologia, Policlinico San Giovanni, Roma, Italy.
Federico RegineUOSD Patologie Retiniche, Fondazione Policlinico di Tor Vergata Roma, Italy;
Policlinico Tor Vergata · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo report the outcome of 5 consecutive cases of presumed, noninfectious endopththalmitis following intravitreal injection of bevacizumab (IVB).

methodsTen pre-loaded syringes of bevacizumab (1.25 mg/50 µL) furnished by a compounding pharmacy were injected intravitreally. Treatments were performed in the operating room by the same surgeon on 2 consecutive days.

resultsOf 10 eyes, 5 showed moderate to severe ocular inflammation within a few days of injection. All patients were treated in the same surgical session. Vitreous tap performed in the patient presenting with the most severe grade of inflammation was negative for bacteria and fungi. At the time of the vitreous biopsy, this patient was injected with vancomycin 1 mg/100 µL in the vitreous cavity. Other eyes with moderate inflammation received topical and systemic antibiotics and topical steroid treatment. Visual acuity returned to pre-endophthalmitis or better levels in all eyes within 1 month. The other 5 patients treated with IVB from the same batch in the other surgical session did not develop inflammation.

conclusionsIVB can induce noninfectious endophthalmitis. The use of compounded syringes can explain clustering of the inflammation. We were unable to identify the reasons for the variable grade of inflammation we observed in our patients.

Indexed as

Visual AcuityAgedAged, 80 and overAngiogenesis InhibitorsBevacizumabDose-Response Relationship, DrugEndophthalmitisFemaleFollow-Up StudiesHumansIntravitreal InjectionsMaleMiddle AgedTime FactorsAngiogenesis InhibitorsBevacizumab

Identifiers

PMID27582674
PMCPMC4990085
OpenAlexW2522843224

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.